Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. (Q33197385)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

title

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

author name string

D P Forward

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

L Jackson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

J F R Robertson

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

language of work or name

English

0 references

publication date

1 February 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

18 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

volume

90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

page(s)

590-594

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

18 November 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409605

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409605

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409605

Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409605

Objective measurement of therapeutic response in breast cancer using tumour markers

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409605

Combined goserelin and tamoxifen in premenopausal advanced breast cancer: duration of response and survival

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409605

Goserelin depot in the treatment of premenopausal advanced breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409605

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601557

Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409605

The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy

31 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601557

Predictors of response to second-line endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601557

The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601557

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601557

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601557

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

21 January 2018

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

12 December 2020

Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer

1 reference

12 December 2020

Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy

1 reference

12 December 2020

On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases

1 reference

12 December 2020

Assessment of response to treatment in advanced breast cancer. British Breast Group

1 reference

12 December 2020

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

1 reference

12 December 2020

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study

1 reference

12 December 2020

Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601557

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

18 November 2019

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14760369%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

PubMed publication ID

14760369

1 reference